Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adams sues Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics filed suit Sept. 27 in U.S. District Court for the District of New Jersey against Perrigo, alleging infringement of Adams' '252 patent for the Mucinex line of extended-release guaifenesin products. The lawsuit responds to the private labeler's filing of a Paragraph IV certification for an ANDA for a 600 mg guaifenesin tablet, equivalent to single-ingredient Mucinex, and initiates a 30-month stay, preventing FDA from approving Perrigo's product unless a court rules against Adams or that period expires (1"The Tan Sheet" Aug. 27, 2007, p. 12)...

You may also be interested in...

Adams Faces Another Mucinex Challenge, Prepares For Product Launches

Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Approved Nearly 75 Years Ago, Bufferin NDA On Withdrawal Notice Due To Registration Lapse

Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts